Paclitaxel 100 mg/16.7 mL
Product Overview
| Generic Name | Paclitaxel 100 mg/16.7 mL |
| Brand Name(s) | Pacliltax, Nanoxel, Z-Taxel, Altaxel, Plaxel |
| Category | Antineoplastic / Cancer |
| Form | Intravenous Multidose vial, Includes solution/albumin‑bound pwdr for reconstitution |
| Strength | 100 mg in 16.7 mL (6 mg/mL) |
| Therapeutic Class | Antimicrotubule taxane agent |
| ATC Code | L01CD01 |
Manufacturing & Regulatory
| Manufacturer | Bristol‑Myers Squibb (Taxol, Abraxane) Teva, Cipla, Glenmark, Ocean Pharma, Fresenius Kabi, Aetos, Biogen, Cipla |
| GMP Compliance | WHO-GMP, FDA-compliant |
| COFEPRIS | Pending |
| Free Sale Certificate | Yes, available as COPP/CPP |
Logistics & Export
| MOQ | 10 Vials |
| Shelf Life | 24 Months |
| Storage | Store at 2–8 °C or 15–25 °C per label |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Supplied per batch upon request |
| SDS-Safety Data Sheet (PDF) | Upon Request |
| CTD Summary (PDF) | CTD from originator; generic use abbreviated formats |
Special Notes
Indications & Usage: Paclitaxel is a taxane-class chemotherapy drug used in ovarian, breast, non‑small cell lung cancer and Kaposi’s sarcoma. It functions by stabilizing microtubules, blocking cell division. Standard regimen: 175 mg/m² IV over 3 hours every 3 weeks (for standard); albumin-bound form at 260 mg/m² over 30 minutes for select indications. Premedication required for hypersensitivity; main toxicities include neuropathy, myelosuppression, and hypersensitivity.